Kymera Therapeutics KYMR Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$69.23M+20.4% | -$86.98M-5.8% | -$82.18M-7.3% | -$76.61M-16.8% | -$65.58M+7.3% | ||
| $2.02M-0.5% | $2.03M-5.4% | $2.15M+3.1% | $2.08M+1.8% | $2.05M+3.1% | ||
| $16.01M+10.8% | $14.45M-8.5% | $15.8M+2.5% | $15.42M+8.3% | $14.23M+3.1% | ||
| —— | $1K-100.0% | $3.86M— | $0— | $0— | ||
| $8.82M+692% | -$1.49M-458% | -$267K+93.5% | -$4.13M-206% | $3.92M+876% | ||
| -$7.21M-153% | $13.66M— | —— | —— | -$11.69M-230% | ||
| $3.57M-30.4% | $5.13M— | $0-100% | $5.08M+283% | -$2.78M— | ||
| -$2.15M— | —— | -$290K— | —— | $694K— | ||
| -$34.37M— | —— | —— | $28.52M+1,458% | -$2.1M+67.4% | ||
| -$88.84M-33.1% | -$66.75M-146% | -$27.11M+54.7% | -$59.88M+24.3% | -$79.15M-28.1% | ||
| $434K+309% | $106K-41.4% | $181K-74.0% | $695K+48.8% | $467K-50.1% | ||
| $276.27M— | —— | $367.56M+531% | $58.25M-30.4% | $83.66M— | ||
| $133.86M— | —— | $132.44M+11.3% | $118.97M-10.4% | $132.74M— | ||
| -$142.84M+63.8% | -$394.4M-67.6% | -$235.3M-492% | $60.02M+23.5% | $48.62M— | ||
| $19.19M— | $0— | $0— | $0— | $0— | ||
| $425K+2.2% | $416K-0.7% | $419K+9.7% | $382K+37.9% | $277K-5.5% | ||
| $18.77M-97.3% | $705.22M+1,685% | $39.51M-83.9% | $245.73M+95,143% | $258K-90.7% | ||
| -$212.91M-187% | $244.07M+209% | -$222.9M-191% | $245.86M+912% | -$30.28M-417% | ||
| $65K-13.3% | $75K-9.6% | $83K+7.8% | $77K0.0% | $77K+24.2% | ||
| —— | $964K0.0% | $964K0.0% | $964K0.0% | $964K-21.7% | ||
| $0— | —— | —— | -$20M-205% | $19.05M+5,249% | ||
| -$1.36M-2.2% | -$1.33M-2.5% | -$1.3M-2.8% | -$1.26M-9.4% | -$1.15M— | ||
| -$615K-3.2% | -$596K+15.8% | -$708K-2.8% | -$689K-2.4% | -$673K-2.3% | ||
| —— | $4.5K0.0% | $4.5K0.0% | $4.5K0.0% | $4.5K+106% | ||
| $3.57M+1,007% | $322K— | —— | $5.08M+283% | -$2.78M-188% | ||
| $133.86M— | —— | $132.44M+11.3% | $118.97M-10.4% | $132.74M— | ||
| —— | -$164.06M0.0% | -$164.06M0.0% | -$164.06M0.0% | -$164.06M— | ||
| $19.19M-60.7% | $48.83M+973% | $4.55M-40.9% | $7.7M+1,340% | $535K-75.4% | ||
| $110K— | —— | $912K— | —— | $357K— | ||
| —— | $257K0.0% | $257K0.0% | $257K0.0% | $257K-62.5% | ||
| -$89.27M-33.5% | -$66.85M-145% | -$27.29M+54.9% | -$60.58M+23.9% | -$79.62M-26.9% | ||
| -$89.27M-33.5% | -$66.85M-145% | -$27.29M+54.9% | -$60.58M+23.9% | -$79.62M-26.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kymera Therapeutics generate?
- Kymera Therapeutics (KYMR) generated -$242.6M in operating cash flow over the trailing twelve months.
- What is Kymera Therapeutics's free cash flow?
- After $1.4M of capital expenditures, Kymera Therapeutics's free cash flow was -$244.0M over the trailing twelve months, down 1.7% year over year.
- Where does Kymera Therapeutics's cash flow data come from?
- Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
